
News|Articles|November 1, 2002
From the ESC Congress: Combination therapy improves LV remodeling in CHF better than monotherapy
Patients with mild chronic heart failure who are treated early on with the beta blocker carvedilol (Coreg) along with the angiotensin-converting enzyme (ACE) inhibitor enalapril demonstrated a significantly greater improvement in left ventricular remodeling than patients receiving either drug alone, according to a 572-patient study presented at the European Society of Cardiology (ESC) Congress in September in Berlin. The results reinforce current treatment recommendations.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CagriSema reduces HbA1c, weight across T2D spectrum in REIMAGINE trials | ADA 2026
2
The women’s health conversation still has a migraine-sized gap
3
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
4
Food as medicine programs changing diabetes care in pediatric and adult patients | ADA 2026
5































